Indication
For routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

Medicine details

Medicine name:
lanadelumab (Takhzyro)
SMC ID:
SMC2206
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Submission type
Full
Status
Publication due date:
Q4 2019
SMC meeting date:
Q4 2019
Patient group submission deadline:
02 September 2019